Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on th...
Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the...
The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quarter of...
The record date will be 5 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023, and The distribution date will be 11:59 p.m. Burlington, North...
SciTech Development today announced it has closed a $2.73M funding round, led by several prominent life science investors to advance clinical trials for No...
Proteologix to receive in-kind products and services to develop treatments for autoimmune/inflammatory diseases and oncology indications Experts from Me...
Non-invasive cardiac diagnostic company Sensydia announced today that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and B...
Responds to global demand for biosafety testing for drug development and commercialization Expansion creates nearly 500 new jobs in Glasgow and Stirling...
Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the ...
Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 ...
Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results ...
© 2025 Biopharma Boardroom. All Rights Reserved.
